Trial Profile
PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (CC-5013) PLUS R-CHOP CHEMOTHERAPY (R2-CHOP) VERSUS PLACEBO PLUS R-CHOP CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED ACTIVATED B-CELL TYPE DIFFUSE LARGE B-CELL LYMPHOMA
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Methylprednisolone; Prednisolone; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ROBUST
- Sponsors Celgene Corporation
- 19 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 16 Oct 2022 This trial has been completed in Netherlands (End Date: 25 July 2022) according to European Clinical Trials Database record.
- 08 Sep 2022 This trial has been completed in Czechia, according to European Clinical Trials Database record.